Treatment of high grade glioma with VM-26 and DDP in 30 cases

doi:10.3969/j.issn.1006-7795.2015.05.024

Abstract

Abstract: Objective To evaluate the safety and efficacy of teniposide (VM-26) and cisplatin (DDP) in the treatment of recurrent malignant glioma. Methods A total of 30 patients were included for this study. The patients were diagnosed with recurrent glioma between 2012/05/01 and 2014/4/30. All patients experience classical STUPP project which contains surgery resection and adjuvant radiotherapy and chemotherapy. The diagnoses were confirmed by the clinical symptoms, contrast-enhanced MRI and the consensus on histology from at least two neuropathologists at the Department of Oncology in Beijing Shijitan Hospital. After the treatment, the image based progression and the adverse events rates were applied to evaluate the results. Results The efficiency for grade Ⅲ glioma patients was 9.1%. The survival rate was 43 months. At the meanwhile, the efficiency for grade Ⅳ was 5.3% and the survival rate was 16 months. The mean overall survival rate of 30 high-grade glioma patients was 18 months. Conclusion The VM-26 and DDP are potential therapeutic agents to treat patients with high-grade malignant recurrent glioma. And VM-26 and DDP have an acceptable safety profile and its adverse events are mostly mild.

Key words: high grade glioma, teniposide, cisplatin

CLC Number:

R651.1

Li Yan, Shi Rui, Chen Jianxin, Li Shan, Kang Xun, Cheng Jing, Zhao Kaihong, Li Wenbin. Treatment of high grade glioma with VM-26 and DDP in 30 cases[J]. Journal of Capital Medical University, 2015, 36(5): 786-790.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2015.05.024

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2015/V36/I5/786

References

[1] Rosenthal M A, Drummond K J, Dally M, et al. Management of glioma in Victoria (1998-2000): retrospective cohort study [J]. Med J Aust, 2006,184(16): 270-273.
[2] Smith S F, Simpson J M, Sekhon L H S. What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades? [J]. J Clin Neurosci, 2005, 12(8):915-920.
[3] Li B, Zhao G, Cheng P, et al. The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression [J]. PLoS One, 2011, 6(10): e25631.
[4] Gladson C L,Prayson R A, Liu W. The pathobiology of glioma tumors [J]. Annu Rev Pathol, 2010, 5: 30-55.
[5] Stewart L A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials [J]. Lancet, 2002,359(9311): 1011-1018.
[6] 张俊英,梁永锯,李永强,等. 恶性脑肿瘤体外化疗药物敏感性试验初步报告[J].广东医学,2003,24(7):715-717.
[7] Stupp R, Mason W, van den Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005,352(10):987-96.
[8] Bower M, Newlands E S, Bleehen N M, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma [J]. Cancer Chemother Pharmacol, 1997, 40(6): 484-488.
[9] 黄强,陈忠平,兰青. 胶质瘤[M]. 北京:中国科技出版社,2000:397-407.
[10] 胡苹,左焕琮,马雄君, 等. O⁶-甲基鸟嘌呤DNA转移酶在神经胶质瘤中的表达及其与亚硝脲耐药的关系[J]. 中日友好医院学报,2003,17(4):216-218.
[11] Silber J R, Bobola M S, Ghatan S, et al. O⁶-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics[J]. Cancer Res, 1998,58(5):1068-1073.
[12] 张俊英,陈忠平. MGMT基因表达与人脑胶质瘤化疗耐药关系研究[J]. 中国神经肿瘤杂志,2003,1(4):200-204.
[13] Perz-Tomas R. Mnltidrug resistance: retrospect and prospects in anti-cancer drug treatment [J]. Curr Med Chem,2006, 13 (16):1859-1876.
[14] Cancer Genome Atlas Research Network.Comprehensive genomic characterization defines human gliobla-stoma genes and core pathways [J]. Nature, 2008, 455(7216):1061-1068.
[15] Cahill D P, Levine K K, Betensky R A, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment [J]. Clin Cancer Res,2007, 13(7): 2038-2045.
[16] Gerstner E R, Ye X, Duda D G, et al. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma [J]. Neuro Oncol, 2015, 17(10): 1386-1392.
[17] Weingart J, Grossman S A, Carson K A, et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial[J]. J Clin Oncol, 2007,25(4):399-404.
[18] Darakchiev B J, Albright R E, Breneman J C, et al. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme[J]. J Neurosurg, 2008,108(2):236-242.
[19] 陈卫峰, 吴倩岚,莫立根. 高级别脑胶质瘤术后3D-CRT与替莫唑胺同步放化疗Meta分析[J]. 中华肿瘤防治杂志,2014,21(7) :543-551.
[20] 唐天友, 许莹莹,王建设,等. 人脑胶质瘤组织MGMT和EGFR及Ki-67表达临床意义分析[J]. 中华肿瘤防治杂志,2013(11) :840-844.
[21] 吕冬芳, 武江,岳向勇. 复发脑胶质瘤的诊断与治疗进展[J]. 临床误诊误治, 2013,26(11) :96-99.
[22] 朱航, 雷迅,张帆,汪洋. 脑胶质瘤危险因素Meta分析及危险因素控制后发病率的变化趋势[J]. 中国医科大学学报, 2012,41(6) :554-558.
[23] 康勋, 李珊,谢铮铮,等. 恶性脑胶质瘤同步放化疗中替莫唑胺化疗的不良反应及对策[J]. 首都医科大学学报,2012,33(5) :589-593.